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The serine protease inhibitor plasminogen activator inhibitor-1 (PAI-1) is increased in several cancers, including 
breast, where it is associated with a poor outcome. Metastatic breast cancer has a dismal prognosis, as evidenced 
by treatment goals that are no longer curative but are largely palliative in nature. PAI-1 competes with integrins 
and the urokinase plasminogen activator receptor on the surface of breast cancer cells for binding to vitronectin. 
This results in the detachment of tumor cells from the extracellular matrix, which is critical to the metastatic 
process. For this reason, we sought to isolate RNA aptamers that disrupt the interaction between PAI-1 and vit-
ronectin. Through utilization of combinatorial chemistry techniques, aptamers have been selected that bind to 
PAI-1 with high affi nity and specifi city. We identifi ed two aptamers, WT-15 and SM-20, that disrupt the interac-
tions between PAI-1 and heparin, as well as PAI-1 and vitronectin, without affecting the antiprotease activity of 
PAI-1. Furthermore, SM-20 prevented the detachment of breast cancer cells (MDA-MB-231) from vitronectin in 
the presence of PAI-1, resulting in an increase in cellular adhesion. Therefore, the PAI-1 aptamer SM-20 demon-
strates therapeutic potential as an antimetastatic agent and could possibly be used as an adjuvant to traditional 
chemotherapy for breast cancer.
Introduction
In the United States, the most prevalent cancer and sec-ond most common cause of death due to cancer in women 
is breast cancer (Cancer Statistics, 2007). Once detected, stag-
ing of the cancer ensues, which determines the therapeutic 
course of action. In addition to surgery, several classes of 
therapeutic agents can be utilized, depending on the nature 
of the cancer. However, many of these therapies, especially 
chemotherapeutic agents, cause side effects that greatly 
diminish the patient’s quality of life. Moreover, if metasta-
ses are discovered, treatment goals are no longer curative 
but are largely palliative in nature, almost exclusively seek-
ing to improve the patient’s comfort as much as possible. 
Therefore, to prevent progression to this stage of disease, 
a nontoxic anticancer agent that represses metastasis could 
serve as an adjuvant to traditional therapeutic agents, possi-
bly reducing the dose necessary for cytotoxicity while less-
ening the adverse effects associated with such therapies.
The serpin plasminogen activator inhibitor-1 (PAI-1; 
SERPINE1) is the main physiological inhibitor of the fi brino-
lysis system, as PAI-1 binds to and inhibits tissue-type plas-
minogen activator (tPA) and urokinase-type plasminogen 
activator (uPA). This results in inhibition of the conversion 
of plasminogen to plasmin. Plasmin cleaves pro-matrix met-
alloproteases (proMMPs), thereby permitting the invasion 
and migration of tumor cells through the MMP-mediated 
proteolytic breakdown of extracellular matrix proteins (for 
review see Dano et al., 2005; Beaulieu et al., 2007). Plasmin 
also directly cleaves components of the extracellular matrix. 
Plasminogen activation is greatly enhanced when uPA 
undergoes high affi nity binding to the urokinase plas-
minogen activator receptor (uPAR). Since PAI-1 inhibits 
uPA activity, one would logically assume that an increase 
in PAI-1 would decrease tumor invasiveness. Surprisingly, 
this is not the case, as increases in expression levels of PAI-1, 
uPA, and uPAR are associated with a poor prognosis for sev-
eral cancers including breast, brain, lung, bladder, liver, and 
pancreatic cancers (Dano et al., 2005; Lah et al., 2006). Many 
investigators have focused on blocking the interaction of 
selected components of the plasminogen activator (PA) sys-
tem given its role in promoting tumor cell progression (Min 
et al., 1996; Ploug et al., 2001; Gondi et al., 2003; Pulukuri 
et al., 2005; Subramanian et al., 2006). For example, direct 
inhibition of uPA with a low-molecular-weight inhibitor 
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WT-15 and SM-20 bind to PAI-1 in a region that spans the 
heparin- and vitronectin-binding domains, inhibiting the 
PAI-1/vitronectin interaction. Moreover, addition of SM-20 
resulted in an increase in breast cancer cell adhesion. This 
aptamer molecule has therefore demonstrated potential as a 
novel antimetastatic therapeutic agent, which upon further 
development could potentially serve as adjuvant therapy for 
breast cancer.
Materials and Methods
Generation of aptamers using systematic evolution of 
ligands by exponential enrichment (SELEX)
The sequence of the starting RNA library (denoted Sel2 
Library) was 5′-GGGAGGACGATGCGG-N40-CAGACG 
ACTCGCTGAGGATCC-3′, where “N40” denotes a ran-
dom region 40-nucleotides in length. The RNA consisted 
of 2′-fl uropyrimidines (2′-fl urocytidine triphosphate and 
2′-fl urouridine triphosphate; Trilink Biotechnologies, San 
Diego, CA) in order to render the RNA nuclease resistant. 
Two separate selections against PAI-1 were performed: one 
selection used human wild-type PAI-1 (hWT PAI-1) protein, 
while the other used human stable mutant PAI-1 (hSM PAI-1), 
which contains four amino acid modifi cations (K154T, Q319L, 
M354I, and N150H) that hold PAI-1 in an active conformation 
(both kindly supplied by Dr. David Ginsburg, University of 
Michigan Medical Center) (Berkenpas et al., 1995). For both 
selections, the RNA library was incubated with its respec-
tive protein for 15 minutes at 37°C; unbound RNA was sepa-
rated from RNA/PAI-1 complexes by passing the mixture 
over a nitrocellulose membrane. The selection against WT 
PAI-1 began in BSA binding buffer E (20 mM Hepes, pH 7.4, 
50 mM NaCl, 2 mM CaCl2, and 0.1% bovine serum albumin 
[BSA]) and continued in this buffer for fi ve rounds. Rounds 
6c and 7c were performed in CHAPS binding buffer E (20 
mM Hepes, pH 7.4, 50 mM NaCl, 2 mM CaCl2, and 0.05% 
CHAPS), and rounds 8c and 9c were performed in CHAPS 
binding buffer F (20 mM Hepes, pH 7.4, 150 mM NaCl, 2 mM 
CaCl2, and 0.05% CHAPS). The selection against hSM PAI-1 
began in BSA binding buffer E and continued in this buffer 
for fi ve rounds. Rounds 6c and 7c were performed in CHAPS 
binding buffer E/F (20 mM Hepes, pH 7.4, 100 mM NaCl, 2 
mM CaCl2, and 0.05% CHAPS), and rounds 8c and 9c were 
performed in CHAPS binding buffer F.
Binding assays
Round and clone binding. Affi nity constants (Kd values) 
were determined using nitrocellulose fi lter binding assays 
as previously described (Rusconi et al., 2000). Briefl y, RNA 
was fi rst dephosphorylated using bacterial alkaline phos-
phatase (Gibco BRL, Gatihersburg, MD) and 5′ end labeled 
with [γ-32P] ATP (PerkinElmer Life And Analytical Sciences, 
Inc., Waltham, MA) using T4 polynucleotide kinase (New 
England Biolabs, Beverly, MA). Round pools of RNA were 
incubated with increasing amounts of their respective PAI-1 
protein in BSA binding buffer E, CHAPS binding buffer E, 
CHAPS binding buffer E/F, or CHAPS binding buffer F, 
depending on the initial round conditions. Following clon-
ing to yield individual aptamer sequences, all binding was 
performed in BSA binding buffer F (20 mM Hepes, pH 7.4, 
150 mM NaCl, 2 mM CaCl2, and 0.1% BSA). Radiolabeled 
retards tumor cell growth and metastasis (Zhu et al., 2007). 
Likewise, low-molecular-weight inhibitors of PAI-1 have 
successfully suppressed cancer cell invasion and angiogene-
sis (Leik et al., 2006). PAI-1 has also been proven responsible 
for the regulation of cellular adhesion and migration, and 
has been shown to interact with several extracellular matrix 
components (Chorostowska-Wynimko et al., 2004; Dellas 
and Loskutoff, 2005). Based on these qualities, many con-
sider PAI-1 to be both a key regulator of tumor progression 
and an ideal target for cancer therapy.
In plasma, PAI-1 exists in two major forms, active and 
latent. While latent PAI-1 is functionally inactive, active 
PAI-1 effectively inhibits target proteases but is labile as it 
spontaneously converts to the latent form (Hekman and 
Loskutoff, 1985; Levin and Santell, 1987; Lindahl et al., 1989). 
To prevent this conversion, active PAI-1 binds to the extra-
cellular matrix protein, vitronectin, which is unable to bind 
inactive PAI-1 or PAI-1 in complex with its target proteases 
(Declerck et al., 1988; Seiffert et al., 1994; Deng et al., 1996). 
Vitronectin also facilitates cell adhesion by binding to inte-
grins and to surface-bound uPA (Wei et al., 1996; Chapman 
and Wei, 2001; Wei et al., 2001). PAI-1 competes with inte-
grins and uPAR for vitronectin binding, resulting in the 
detachment of cells from the extracellular matrix (Deng et 
al., 1996; Stefansson and Lawrence, 1996; Kjoller et al., 1997). 
Therefore, the binding of PAI-1 to vitronectin prevents integ-
rins from binding to vitronectin and inhibits cell adhesion in 
some cells, particularly breast cancer cells (Deng et al., 1996; 
Stefansson and Lawrence, 1996; Kjoller et al., 1997; Redmond 
et al., 2001; Palmieri et al., 2002). Therefore, the concentration 
of PAI-1, as well as the presence or absence of vitronectin, 
plasminogen activators, thrombin, and low-density lipopro-
tein receptor-related protein (LRP), all appear to play a role 
in the PAI-1-mediated effect on cell migration.
To shift the balance of the PA system toward cell adhe-
sion, we exploited the properties of nucleic acid ligands 
termed aptamers. Aptamers are relatively small (~8–15 kDa) 
single-stranded nucleic acid ligands that bind to their tar-
gets with high affi nity and specifi city. In addition, they are 
nontoxic, have low to no immunogenicity, can be synthet-
ically manufactured, and have adjustable bioavailability 
(EyetechStudyGroup, 2002; Nimjee et al., 2005). Therefore, 
aptamers possess the affi nity properties of monoclonal 
antibodies, while retaining the ease of synthesis of small 
molecules. For these reasons, aptamers are ideal agents for 
disrupting protein–protein interactions. Following the 2004 
FDA approval of the fi rst aptamer-based therapeutic agent, 
pegaptanib, a number of aptamers have entered clinical trials; 
for example, the aptamer targeting the interaction between 
Factor IXa and its substrate Factor X is currently in Phase 2 
clinical trials as an antithrombotic agent with applications 
for percutaneous coronary intervention and generalized 
surgical anticoagulation (EyetechStudyGroup, 2003; Dyke et 
al., 2006; Chan et al., 2008a, 2008b). In this study, we hypoth-
esized that RNA aptamers that target the PAI-1/vitronectin 
interaction would increase cancer cell adhesion, which may 
translate to a clinical application in reducing breast cancer 
metastasis. To test this hypothesis, we generated aptamers 
that specifi cally bind to PAI-1 with high affi nity (Kd < 4 nM) 
using SELEX (systematic evolution of ligands by exponential 
enrichment). Through functional assays including mutagen-
esis studies, competition binding, chromogenic assays, and 
cell adhesion experiments, we determined that aptamers 
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to 200 ng/mL PAI-1-A (active fraction of wild-type PAI-1, 
Molecular Innovations, Inc., Novi, MI) for a fi nal volume of 
200 μL. The RNA/PAI-1 mixture was incubated at RT for 10 
minutes prior to its addition to the blocked plate, which then 
incubated at RT for 30 minutes. The plate was then washed 
three times with PBST and blotted on a paper towel, and 150 
μL uPA (Molecular Innovations, Inc., Novi, MI) was added to 
the plate for a fi nal concentration of 1 nM; this was incubated 
at RT for 30 minutes. Next, 50 μL S-2444 (DiaPharma, West 
Chester, OH), the chromogenic substrate for uPA activity, 
was added to the plate, which was then immediately placed 
into a microplate reader (BioTek EL311; BioTek Instruments, 
Inc., Winooski, VT) and set for kinetic readings every 35 sec-
onds for 15 minutes at an absorbance of 405 nm. All RNA and 
protein were diluted in PBS with calcium and magnesium.
Thrombin activity assays
Heparin-mediated PAI-1 inhibition of thrombin. Increasing 
amounts of aptamer clones SM-20 and WT-15 (as well as the 
Sel2 library as a negative control) were heated to 65°C for 5 
minutes and incubated with 50 nM WT PAI-1-A (active frac-
tion of wild-type PAI-1; Molecular Innovations, Inc., Novi, 
MI) for 10 minutes at room temperature. Heparin (Diosynth 
Oss, the Netherlands; 10 μg/mL) and 1 nM α-thrombin 
(Haematologic Technologies, Inc., Essex Junction, VT) were 
then added to the RNA/PAI-1 mixture to bring the fi nal 
volume to 100 μL and incubated at room temperature for 
30 minutes. Residual thrombin activity was determined by 
cleavage of the chromogenic reagent specifi c for thrombin 
activity, S-2238 (DiaPharma, West Chester, OH) (150 μM). The 
plate was then immediately placed into a microplate reader 
(BioTek EL311; BioTek Instruments, Inc., Winooski, VT) and 
set for kinetic readings every 35 seconds for 15 minutes at an 
absorbance of 405 nm. All RNAs and proteins were diluted 
in HNPN buffer (20 mM Hepes, 150 mM NaCl, 0.01% PEG, 
0.005% sodium azide).
Vitronectin-mediated PAI-1 inhibition of thrombin. When vit-
ronectin was used to mediate PAI-1 inhibition of thrombin, 
the protocol remained unchanged with the exception that 10 
μg/mL vitronectin (Molecular Innovations, Inc., Novi, MI) 
was used as opposed to heparin.
Cell adhesion assay
All cell adhesion assays were performed in 96-well 
microtiter plates that were coated with 150 μL vitronectin 
(Molecular Innovations, Inc., Novi, MI) at 7.5 μg/mL for 1 
hour at 37°C. The plates were washed three times with warm 
PBS, and blocked for 1 hour at 37°C with 1% heat-inactivated 
BSA. The plates were then washed three times with PBS, air-
dried, and either used immediately or wrapped in parafi lm, 
and stored at 4°C. Aptamers WT-15 and SM-20 (as well as 
the Sel2 library as a negative control) (50–1000 nM) were 
heated to 65°C for 5 minutes prior to adding 50 nM PAI-1-A 
(Molecular Innovations, Inc., Novi, MI) for a fi nal volume of 
50 μL. The RNA/PAI-1 mixture was then incubated at 37°C 
for 15 minutes. MDA-MB-231 breast cancer cells were seeded 
at 5 × 104 cells/well in 200 μL serum-free medium onto vit-
ronectin-coated plates and were allowed to attach for 1 hour 
at 37°C in the presence of PAI-1 or the RNA/PAI-1 complex. 
Following incubation, the nonadherent cells were removed 
with a multichannel pipette, and adhered cells were washed 
RNA was incubated with PAI-1 protein for 5 minutes at 
37°C; the mixture was then passed over a nitrocellulose 
membrane. The fraction of RNA that bound to the pro-
tein was quantifi ed using a phosphoimager (Molecular 
Dynamics, Sunnyvale, CA). Nonspecifi c binding of the RNA 
was subtracted out such that only specifi c binding remained 
(denoted “corrected fraction bound”).
Competition binding. To determine if heparin and vitronec-
tin were able to compete with aptamers WT-1, WT-15, and 
SM-20 for binding to PAI-1, the aptamers were fi rst dephos-
phorylated and radiolabeled as described earlier. Briefl y, 
a constant amount of PAI-1 (378 pM for WT-1, 888 pM for 
WT-15, and 3.4 nM for SM-20 when competing with heparin; 
888 pM for WT-15 and 2.2 nM for SM-20 when competing 
with vitronectin) was incubated with increasing amounts 
of heparin or vitronectin at 37°C for 5 minutes. The PAI-1/
competitor solution was then combined with a trace amount 
of radiolabeled aptamer and incubated at 37°C for 5 min-
utes before passing the mixture over a nitrocellulose mem-
brane. The fraction of RNA bound to the protein was then 
quantifi ed using a phosphoimager (Molecular Dynamics, 
Sunnyvale, CA).
PAI-1 complex formation
PAI-1 forms a high-molecular-weight, SDS-stable com-
plex with tPA, uPA, and thrombin/heparin (Ehrlich et al., 
1991; Perron et al., 2003) that can be visualized by SDS-PAGE. 
For that reason, we used SDS-PAGE analysis to evaluate the 
infl uence of the aptamers on the reaction products gener-
ated during the interaction of PAI-1 with its target proteases. 
The aptamers (500–1000 nM) were incubated with PAI-1 (500 
nM; Molecular Innovations, Novi, MI) at 37°C for 10 minutes 
in HNPN buffer (20 mM Hepes, 150 mM NaCl, 0.01% PEG, 
0.005% sodium azide) containing CaCl2 (2 nM), prior to the 
addition of proteases (tPA [Molecular Innovations, Novi, 
MI] or thrombin [Haematologic Technologies, Inc., Essex 
Junction, VT]). The aptamers were fi rst heated to 65°C for 5 
minutes before use. PAI-1/aptamer was then incubated with 
tPA (400 nM) for 15 minutes or with thrombin/heparin (200 
nM and 10 μg/mL heparin) for 60 minutes at 37°C. The reac-
tions were stopped through the addition of Laemmli buffer 
containing β-mercaptoethanol and were boiled for 5 minutes. 
The reactions were fi nally analyzed by SDS-PAGE followed 
by Coomassie staining to visualize PAI-1, thrombin, and tPA 
bands, as well as PAI-1/tPA and PAI-1/thrombin complexes.
Solid-phase vitronectin studies
Solid-phase PAI-1 binding studies were performed accord-
ing to Lawrence et al., with slight modifi cation (Lawrence et 
al., 1990). Briefl y, 96-well plates used for immunochemistry 
(Nunc Immuno-module, Nalge Nunc International, Thermo 
Fisher Scientifi c, Rochester, NY) were coated with 150 μL of 
vitronectin (Molecular Innovations, Inc., Novi, MI) at 250 ng/
mL and allowed to incubate overnight at 4°C. The wells were 
then washed three times with 300 μL PBST (phosphate buff-
ered saline with 0.01% Tween 20). Following drying at room 
temperature (RT) for 15 minutes, the plate was blocked with 
3% BSA for 1 hour at RT, followed by three washes with PBST. 
After heating an increasing amount of WT-15 and SM-20 (as 
well as the Sel2 library as a negative control) to 65°C for 5 
minutes and allowing for cooling, the aptamers were added 
03_OLI-2009_0177.indd   119 5/18/2009   12:17:53 PM
BLAKE ET AL.120
two versions of human PAI-1. The native wild-type form of 
PAI-1 was used (hWT PAI-1), as well as a stable mutant ver-
sion (hSM PAI-1) that contains the amino acid changes K154T, 
Q319L, M354I, and N150H that stabilize the otherwise labile 
protein in an active conformation (Berkenpas et al., 1995). 
First, a starting RNA library modifi ed with 2′-fl uoropyrimi-
dines was bound with each protein; the RNA that bound to 
PAI-1 was separated from unbound RNA using a nitrocellu-
lose membrane as described in Materials and Methods. By 
increasing the stringency in subsequent rounds, the bind-
ing affi nity of each round increased (Fig. 1A and 1B). After 
nine rounds of SELEX, the affi nity of the rounds reached 
low nanomolar levels. The round nine library (R9c) was 
then cloned and sequenced to generate individual aptamer 
sequences, as shown in Table 1. The WT selection produced 
only three aptamers, one of which, WT-1, dominated the pool 
of aptamers (Table 1). The SM selection, however, yielded 
a family of aptamers with similar sequences and several 
additional aptamers. Each WT aptamer (WT-1, WT-15, and 
twice with warm PBS. To determine the quantity of adherent 
cells, an MTT assay was performed. Briefl y, 20 μL of MTT 
(5 mg/mL) in 200 μL of serum-free media was added to each 
well and incubated for 3 hours at 37°C. Following incuba-
tion, the media was removed and 100 μL dimethyl sulfoxide 
(DMSO; Sigma, St. Louis, MO) was added to solubilize the 
formazan crystals for 15–30 minutes at room temperature. 
The absorbance was then measured at 570 nm in a VersaMax 
microtiter plate reader (Molecular Devices). The background 
absorbance was measured at 690 nm, which was subtracted 
from the absorbance at 570 nm.
Results
Nine rounds of SELEX yielded aptamers that 
bind to PAI-1 with high affinity
In order to generate aptamers that bound to the active form 
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FIG. 1. Systematic evolution of ligands by exponential enrichment (SELEX) yielded aptamers that bind to plasminogen 
activator inhibitor-1 (PAI-1) with high affi nity. (A) The progress of the selection against the wild-type (WT) version of PAI-1 
was followed using a nitrocellulose fi lter binding assay. Inverted triangles (▼) represent the starting RNA library (Sel2). 
Diamonds (◆) represent round 3, circles (●) represent round 5, triangles (▲) represent round 7, and squares (■) represent 
round 9. The x-axis shows the human wild-type PAI-1 concentration and the y-axis shows the fraction of RNA bound to the 
protein. (B) The progress of the selection against the stable mutant (SM) version of PAI-1 was followed using a nitrocellulose 
fi lter binding assay. Inverted triangles (▼) represent the starting RNA library (Sel2). Diamonds (◆) represent round 3, circles 
(●) represent round 5, triangles (▲) represent round 7, and squares (■) represent round 9. The x-axis shows the human stable 
mutant PAI-1 concentration and the y-axis shows the fraction of RNA bound to the protein. (C) Binding affi nities of aptamers 
WT-1, WT-15, and WT-18 generated against WT PAI-1 were determined using a nitrocellulose fi lter binding assay. Squares 
(■) represent WT-1, triangles (▲) represent WT-15, and inverted triangles (▼) represent WT-18. Each data point was per-
formed in triplicate; error bars represent the standard error of the mean (SEM) of the data. (D) Binding affi nities of aptamers 
SM-2, SM-20, and SM-23 generated against SM PAI-1 were determined using a nitrocellulose fi lter binding assay. Squares (■) 
represent SM-2, triangles (▲) represent SM-20, and circles (●) represent SM-23. Each data point was performed in triplicate; 
error bars represent the SEM of the data.
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disrupt the complex (Fig. 3A). These data further suggest that 
the aptamers compete with heparin for binding to PAI-1.
The antiproteolytic activity of PAI-1 is dependent on its 
ability to form a stable complex with the plasminogen acti-
vators tPA and uPA. To determine if the aptamer clones were 
able to disrupt the PAI-1/tPA interaction, aptamers WT-15 
and SM-20 were incubated with PAI-1, followed by addition 
of tPA. Figure 3B does not demonstrate any decrease in the 
level of PAI-1/tPA complex, suggesting that these aptamers 
do not interfere with the interaction of PAI-1 with tPA. These 
data suggest that the aptamers do not disrupt the antiprote-
olytic function of PAI-1.
Aptamers WT-15 and SM-20 prevent PAI-1 from 
binding to solid-phase vitronectin
In vivo, vitronectin, an adhesive glycoprotein, binds to the 
extracellular matrix (Preissner, 1991). Therefore, although 
heparin and vitronectin competed with the clones for bind-
ing to PAI-1 in solution, we sought to determine if the clones 
could prevent PAI-1 from binding to vitronectin in a solid 
phase. In this assay, PAI-1 or PAI-1/RNA complex was added 
to vitronectin-coated plates and incubated as described in 
Materials and Methods. Following incubation, the plate was 
washed and incubated with uPA. If PAI-1 retains the ability 
to bind to vitronectin, it will inhibit uPA activity. As shown 
in Figure 4A, when only vitronectin is present, without PAI-1 
or aptamers, uPA has maximal activity; the same is true 
when PAI-1, but no vitronectin, is present. As anticipated, 
the combination of vitronectin and PAI-1 decreases uPA 
activity ~60%. Aptamer WT-15 fully restores uPA activity 
and SM-20 restores uPA activity to greater than 90%, indicat-
ing that their binding to PAI-1 precludes binding to vit-
ronectin. Figure 4B shows a dose–response curve of aptamer 
WT-18) and selected aptamers from the SM selection were 
then chosen to undergo further characterization. As seen 
in Figure 1C and 1D, aptamers generated from both the WT 
and SM selections bound to WT PAI-1 with high affi nity, as 
evidenced by their low nanomolar/high picomolar affi nity 
constant (Kd) values (Table 1).
Heparin and vitronectin compete with clones WT-15 
and SM-20 for binding to PAI-1
To determine the specifi c binding region of the lead 
aptamers, competition binding with heparin, given its sim-
ilar charge distribution to RNA, and vitronectin, due to its 
proximity to the heparin-binding site, was performed. In this 
assay, a fi xed amount of PAI-1 was incubated with increas-
ing amounts of heparin or vitronectin, which was then com-
bined with a trace amount of RNA. Protein competition with 
RNA for binding to PAI-1 is seen as a decrease in the fraction 
of RNA bound to PAI-1. As shown in Figure 2A, increasing 
amounts of heparin abolished binding of aptamer clones 
WT-1, WT-15, and SM-20 to PAI-1. In a like manner, competi-
tion binding was tested with vitronectin and similar results 
were attained with WT-15 and SM-20 (Fig. 2B). Therefore, 
heparin and vitronectin compete with WT-15 and SM-20 for 
binding to PAI-1 in solution, implying that these aptamers 
bind to PAI-1’s heparin-/vitronectin-binding domains.
PAI-1 forms a SDS-stable complex with thrombin in the 
presence of heparin (Ehrlich et al., 1991). Therefore, if the 
aptamers prevent heparin binding to PAI-1, one would sus-
pect that they will also disrupt the stable complex between 
PAI-1 and thrombin. Figure 3A shows that the aptamers 
(WT-15 and SM-20) are able to disrupt the complex in a con-
centration-dependent manner, as evidenced by the cleaved 
complex. The control aptamer library (Sel2) is unable to 
Table 1. PAI-1 Aptamer Sequences




R9chWT-1 5′-GTCCTAGCAGACACTCGGCCATCACGCCCATTGGTTTGCA-3′ 89 1.2 nM
R9chWT-15 5′-ATCAACTCACCGTAGGTCTAGTGAGAACTTCAAGTCTACT-3′ 5 177 pM
R9chWT-18 5′-ACTCCAACGATCCCACCGCGACAAGGGTCATCGGCACCGT-3′ 5 35 nM
Selected against SM
R9chSM-20 5′-AGCGACTGACGATCTTGAGTAAACCGCTCATCCACGTAGT-3′ 15 920 pM
R9chSM-14 5′-GTCCAGCTAAATCTCTACGAACCCCGCATTCCCCGTAACT-3′ 10 37 nM
R9chSM-3 5′-GTCTCAATACGCACCCTGCATTCCCTTACTCGAGCCTAGC-3′ 10 106 nM
R9chSM-23 5′-ATCTTTGGCCCTCCACAATATCCCTCCATGGGGTACCAG-3′ 5 24 nM
R9chSM-2 5′-ATCCACTACGAACTCCGCATTCCCAGACACACTGGACCT-3′ 5 3.3 nM
R9chSM-7 5′-GTCAAGNACGCGAACCCCGCATTCCCAAGAACGGCAACCCT-3′ 5 120 nM
R9chSM-24 5′-TATCAACTAACGTACTGCCGCATTCCCACAATCCACAGGCTCC-3′ 5 60 nM
R9chSM-6 5′-NTCAGTAAACGAACTCCGTATTCCCGATCATATGAGCACG-3′ 5 ND
R9chSM-16 5′-NTCACTCCAACGAACTCCGCATTCCCACACGCGACAATA-3′ 5 ND
R9chSM-8 5′-ATCAGGTACGAACTCTGCATTCCCAAAGCTCTCGGGGTGT-3′ 5 ND
R9chSM-5 5′-GTCAGGACTCAACTACGAACCCCGCATTCCCAACAGCACT-3′ 5 ND
R9chSM-9 5′-GTCAACCTCACGAACCCCGCATTCCCAGAGCCACTGCTCT-3′ 5 ND
R9chSM-17 5′-GTCAATTCAGCCACGTACCCCGCATTCCCAATGCCAGCAT-3′ 5 ND
R9chSM-12 5′-GTCAGCCTACGAACCCCGCATTCCCGATCGGGCCCGGCA-3′ 5 ND
R9chSM-18 5′-GTCATATCAACGAACCCCGCATTCCCGAGTAACTCCACCT-3′ 5 ND
Abbreviation: ND, not determined.
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either heparin or vitronectin prior to addition of thrombin. 
Residual thrombin activity was determined as described in 
Materials and Methods. In Figure 5A, we show that thrombin 
is inhibited by PAI-1/heparin, as evidenced by the decrease 
in thrombin activity. On the other hand, when PAI-1/hepa-
rin is incubated with 1 μM WT-15 or 1 μM SM-20, thrombin 
activity is completely restored. This rescue was also found to 
be dose-dependent, as seen in Figure 5B. Moreover, a decline 
in maximal restoration was not observed until the concen-
tration of the clones reached below 62.5 nM. Similar results 
were found when in the presence of vitronectin (Fig. 5C and 
5D). Here, the PAI-1/vitronectin had a more profound effect, 
decreasing thrombin activity to ~15% of its original value. 
As seen in Figure 5C, 5 μM WT-15, as well as 5 μM SM-20, 
restored ~65% of thrombin activity. Again, this occurred in a 
dose-dependent manner (Fig. 5D). Consequently, these data 
show that the aptamers WT-15 and SM-20 were able to pre-
vent a functional reaction that stemmed from PAI-1 binding 
to heparin or vitronectin.
Aptamer SM-20, but not WT-15, restores breast 
cancer cell adhesion
Because both SM-20 and WT-15 prevented PAI-1 from 
binding to vitronectin bound to a solid surface and also dis-
rupted a functional reaction involving PAI-1 and vitronectin, 
we sought to translate our results from in vitro to cell culture 
restoration of uPA activity; we see that near  maximal levels 
of uPA activity, and thus inhibition of PAI-1 binding to vit-
ronectin, occurs at concentrations as low as 12.5 nM.
Aptamers WT-15 and SM-20 prevent heparin- and 
vitronectin-mediated PAI-1 inhibition of thrombin
In addition to preventing the binding of heparin and vit-
ronectin to PAI-1, we sought to determine if this translated 
to an inhibition of PAI-1 function. To this end, we tested the 
ability of the aptamer clones to impede thrombin inhibition 
by PAI-1 that is mediated by the cofactors heparin or vitronec-
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FIG. 2. Heparin and vitronectin compete with aptamers 
for binding to PAI-1 in solution. (A) Increasing amounts 
of heparin compete with aptamers for binding to PAI-1; 
squares (■) represent competition with clone WT-1 (PAI-1 
concentration, 378 pM), triangles (▲) represent competition 
with WT-15 (PAI-1 concentration, 888 pM), and circles (●) 
represent competition with SM-20 (PAI-1 concentration, 3.4 
nM). The x-axis shows the concentration of heparin, while 
the y-axis shows the fraction of RNA bound to PAI-1. (B) 
Increasing amounts of vitronectin compete with clones for 
binding to PAI-1; triangles (▲) represent competition with 
WT-15 (PAI-1 concentration, 888 pM), while circles (●) repre-
sent competition with SM-20 (PAI-1 concentration, 2.2 nM). 
The x-axis shows the concentration of vitronectin, while the 















FIG. 3. Aptamers WT-15 and SM-20 disrupt the PAI-1/
thrombin/heparin complex without affecting the PAI-1/
tPA complex. (A) SM-20 and WT-15 disrupt the thrombin/
PAI-1 complex in a concentration-dependent manner. PAI-1 
(500 nM) was incubated with WT-15 (lanes 5 and 8), SM-20 
(lanes 6 and 9), or Sel2 (lanes 7 and 10) (500–1000 nM) for 10 
minutes before addition of thrombin (200 nM) and heparin 
(10 μg/mL). Lane 1: MW marker; lane 2: PAI-1 alone; lane 3: 
thrombin alone; lane 4: PAI-1/thrombin/heparin; lanes 5, 6, 
7: aptamers at 500 nM; lanes 8, 9, 10: aptamers at 1000 nM. (B) 
The aptamers are unable to disrupt the PAI-1/tPA complex. 
PAI-1 (500 nM) was incubated with WT-15, SM-20, or Sel 2 
(500 nM) prior to adding tPA (400 nM). Lane 1: MW marker; 
lane 2: PAI-1 alone; lane 3: tPA alone; lane 4: PAI-1/tPA; lane 
5: PAI-1/tPA/WT-15; lane 6: PAI-1/tPA/SM-20; lane 7: PAI-1/
tPA/Sel2.
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to increase breast cancer cell adhesion in the presence of 
PAI-1 at concentrations up to 1000 nM (Fig. 6B).
Discussion
PAI-1 is a multifunctional protein that interacts with several 
macromolecular substrates including plasminogen activators, 
vitronectin and thrombin. It contains three major domains, 
the active site region, the vitronectin-binding domain, and 
the lipoprotein-related protein-binding domain—all of which 
have been shown to contribute to the PAI-1-mediated patho-
genesis of various diseases, including cancer (Wu and Zhao, 
2002). In this study, we demonstrated that a PAI-1-specifi c 
RNA aptamer that binds to the vitronectin/heparin-binding 
sites of PAI-1 is able to restore breast cancer cell adhesion.
Considering the role of PAI-1 in cancer cell progression 
and metastasis, these data support the development of 
aptamers as a therapeutic option for cancer management. 
Aptamers have been shown to be nontoxic, well-tolerated 
molecules that cause low to no immunogenicity, can be syn-
thetically manufactured, and have an adjustable bioavail-
ability (EyetechStudyGroup, 2002; Nimjee et al., 2005; Dyke 
et al., 2006; Chan et al., 2008a, 2008b). In addition to targeting 
PAI-1 for reductions in breast cancer metastasis, RNA aptam-
ers have been selected that inhibit osteopontin, a secreted 
phosphoprotein that mediates tumorigenesis, local growth, 
and metastasis in several cancers (Mi et al., 2008). It has been 
shown that addition of OPN-R3 inhibits MDA-MB-231 in 
vitro adhesion, migration, and invasion, and decreases local 
progression and distant metastases in an in vivo xenograft 
model of breast cancer (Mi et al., 2008).
We describe the fi rst RNA aptamer that binds PAI-1 while 
inhibiting the binding of PAI-1 to vitronectin. However, 
complete inhibition of all of PAI-1’s activities might hinder 
its ability to regulate fi brinolysis, which could in principle 
engender bleeding. Therefore, elimination of the patholog-
ical functions of PAI-1 without hindering its physiological 
functions in hemostasis would be benefi cial in a variety of 
disease settings. Here we demonstrated that aptamers WT-15 
and SM-20 are able to disrupt vitronectin binding without 
compromising PAI-1’s other functions, such as the inhibition 
of plasminogen activators.
The interaction between PAI-1 and vitronectin is critical 
to cancer progression. Given the importance of the PAI-1/
vitronectin interaction in disrupting cellular adhesion, we 
hypothesized that an aptamer that inhibits this interaction 
would have a therapeutic application for breast cancer metas-
tasis. To investigate this hypothesis, we fi rst used SELEX 
technology targeting the human wild type (WT) and consti-
tutively active stable mutant (SM) versions of PAI-1 to better 
ensure selection of an aptamer that bound the active version 
of PAI-1 (as opposed to the latent conformation). After nine 
rounds of SELEX, the enriched RNA pools were cloned and 
sequenced to generate individual aptamer sequences. The 
three aptamers that bound to WT or SM PAI-1 with the high-
est affi nities were chosen for further characterization (WT-1, 
WT-15, and WT-18 from the WT selection, as well as SM-2, 
SM-20, and SM-23 from the SM selection). Following these 
assays, the two aptamers possessing binding affi nities for 
WT PAI-1 in the picomolar range, WT-15 and SM-20, were 
found to have the greatest potential for disruption of the 
PAI-1/vitronectin interaction; hence, those clones were car-
ried forward into all additional assays.
and test the PAI-1-specifi c aptamers’ ability to disrupt a 
clinically relevant reaction, restoration of breast cancer cell 
adhesion. In this assay, breast cancer cells (MDA-MB-231) 
are incubated with PAI-1 or PAI-1/aptamer on vitronectin-
coated plates. As seen in Figure 6, the addition of 50 nM 
PAI-1 decreases cell adhesion ~60%. However, the addition 
of increasing amounts of clone SM-20, with an optimal con-
centration at 500 nM, increases the percentage of cells that 
remain adherent to vitronectin (Fig. 6A). Although WT-15 






































































































FIG. 4. Aptamers SM-20 and WT-15 prevent PAI-1 from 
binding to vitronectin that is bound in a solid phase. (A) Both 
200 nM SM-20 and 200 nM WT-15 restore uPA activity, which 
indicates that they were able to free uPA from PAI-1 inhibi-
tion mediated by binding to vitronectin coated on a plate. 
Each data point was performed in duplicate in three separate 
experiments; error bars represent the standard error of the 
mean (SEM). (B) Clones SM-20 (represented by squares [■]) 
and WT-15 (represented by triangles [▲]) restore uPA activ-
ity in a dose-dependent manner by preventing PAI-1 from 
binding to vitronectin and hence inhibiting uPA. Each data 
point was performed in duplicate in three separate experi-
ments; error bars represent the SEM.
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Considering this, and the fact that PAI-1 is a heparin-bind-
ing serpin, we suspected that our aptamers would have a 
high probability of binding in the vicinity of this site. Also, 
PAI-1’s vitronectin-binding site is located near the heparin-
binding site. Consequently, we hypothesized that if our 
aptamer binds to the heparin site, it may also have an effect 
on vitronectin binding.
Aptamers tend to bind to highly positive regions on pro-
teins such as heparin-binding sites. For example, the throm-
bin aptamer (TOG25) binds thrombin’s heparin-binding site 
and has been shown to eliminate the heparin-accelerated 
inhibition of thrombin by various serpins (Jeter et al., 2004), 
and the VEGF aptamer that inhibits angiogenesis binds to 











































































































































































































































































FIG. 5. Aptamers SM-20 and WT-15 prevent heparin- and vitronectin-mediated PAI-1 inhibition of thrombin. (A) 1 μM 
SM-20, as well as 1 μM WT-15, restored thrombin activity despite the presence of PAI-1 and heparin, which in combination 
inhibited thrombin activity. Each data point was performed in duplicate in three separate experiments; error bars repre-
sent the standard error of the mean (SEM). (B) SM-20 (represented by squares [■]) and WT-15 (represented by triangles 
[▲]) restore thrombin activity following PAI-1 and heparin inhibition in a dose-dependent manner. Each data point was 
performed in duplicate in three separate experiments; error bars represent the standard error of the mean (SEM). (C) 5 μM 
SM-20, as well as 5 μM WT-15, restored thrombin activity despite the presence of PAI-1 and vitronectin, which in combina-
tion inhibited thrombin activity. Each data point was performed in duplicate in three separate experiments; error bars repre-
sent the SEM. (D) Aptamers SM-20 (represented by squares [■]) and WT-15 (represented by triangles [▲]) restore thrombin 
activity following PAI-1 and vitronectin inhibition in a dose-dependent manner. Each data point was performed in duplicate 
in three separate experiments; error bars represent the SEM.
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heparin-binding region, as aptamer binding to this mutant 
protein was greatly reduced (data not shown). These results 
led us to hypothesize that the aptamers bind in the vicinity 
of PAI-1’s heparin-binding site. To test this hypothesis, we 
investigated the ability of heparin to compete with aptamer 
binding to PAI-1. As seen in Figure 2A, increasing amounts 
of heparin prevented aptamer binding to PAI-1, suggesting 
that heparin binds in an overlapping site with the aptamers. 
When this assay was repeated with vitronectin as a com-
petitor, similar results were achieved (Fig. 2B); however, at 
higher concentrations of vitronectin, binding somewhat 
increased. This was most likely due to nonspecifi c RNA 
interactions with high concentrations of vitronectin (data 
not shown). Recent studies have provided evidence that 
there are two vitronectin-binding sites on PAI-1, the somato-
medin B (SMB) domain and another site outside of the SMB 
domain (Schar et al., 2008). Consequently, another plausible 
explanation is that the aptamers may also bind to the second 
vitronectin-binding site on PAI-1, although with reduced 
affi nity. Nevertheless, collectively these data suggest that 
the clones bind to PAI-1 in a region spanning both the hep-
arin- and vitronectin-binding domains (α-helices D and E, 
respectively).
Vitronectin is a main component of the extracellular 
matrix and is involved in several physiological processes 
including cell adhesion, migration, and proliferation, as 
well as fi brinolysis (Preissner, 1991). Whereas we were able 
to show that the aptamers bound to PAI-1 in a region over-
lapping the heparin- and vitronectin-binding sites, we did 
not know if this translated to the in vivo environment, that 
is, when vitronectin is bound to the extracellular matrix. 
Therefore, to further characterize the binding location and 
function of the clones, we performed an assay to deter-
mine if the clones were able to prevent PAI-1 from bind-
ing to vitronectin bound in a solid phase. We showed that 
both aptamers decreased PAI-1 inhibition of uPA (indicating 
that PAI-1 was not bound to vitronectin) in the presence of 
bound vitronectin (Fig. 4). Aptamer WT-15 fully attenuated 
PAI-1 inhibition of uPA, and such inhibition decreased only 
when its concentration became less than the concentration of 
PAI-1 in the assay (4.54 nM). This observation suggests that 
aptamer WT-15 binds to PAI-1 in a 1:1 stiochiometric ratio.
In addition to preventing PAI-1 from binding to vitronec-
tin, aptamers WT-15 and SM-20 were found to disrupt the 
functional interaction between vitronectin and PAI-1 as it 
relates to thrombin inhibition (Fig. 5). Similar results were 
found when heparin was used as the cofactor, as both hepa-
rin and vitronectin accelerate PAI-1’s inactivation of thrombin 
more than 200-fold, primarily by facilitating the formation 
of noncovalent complexes (Naski et al., 1993; Rezaie, 1999). 
Similar to the results noted for solid-phase vitronectin bind-
ing, aptamers WT-15 and SM-20 attenuated PAI-1/heparin 
and PAI-1/vitronectin inhibition of thrombin activity in a 
dose-dependent manner. Inhibition was particularly robust 
for the PAI-1/heparin interaction (Fig. 5B), as a decrease in 
maximal thrombin inhibition was again not apparent until 
the concentration of the aptamers was less than the concen-
tration of PAI-1, further suggesting that the aptamers bind 
to PAI-1 in a 1:1 manner. On the other hand, the attenuation 
of the inhibition of PAI-1/vitronectin by the aptamers was 
not as robust as seen with heparin. One potential explana-
tion is that at high concentrations of RNA, vitronectin non-
specifi cally binds RNA, reducing the amount available to 
The fi rst step in determining if the RNAs were able to 
disrupt the PAI-1/vitronectin interaction was to elucidate 
their binding location. When the aptamers were added 
to PAI-1 and uPA in a chromogenic assay used to detect 
uPA activity, no restoration of uPA function was found 
(data not shown). In addition, these aptamers were unable 
to disrupt the PAI-1/tPA high-molecular-weight com-
plex (Fig. 3B). These observations led us to conclude that 
the aptamers were not binding to PAI-1 in a region (most 
likely the reactive center loop of PAI-1) that is important for 
its direct inhibition of uPA. Subsequently, we investigated 
the heparin-binding site of PAI-1. Binding studies with the 
PAI-1 R76E mutant (Stefansson et al., 1998), which does not 








































































































































































































FIG. 6. Aptamer SM-20, but not WT-15, restores breast can-
cer cell adhesion. (A) Breast cancer cells (MDA-MB-231) were 
incubated in the presence of SM-20 and PAI-1 in a vitronec-
tin-coated plate. The SM-20 were performed in duplicate; 
error bars represent the standard error of the mean (SEM). 
(B) Breast cancer cells (MDA-MB-231) in the presence of 
WT-15 and PAI-1 in a vitronectin-coated plate did not show 
evidence of increased adhesion.
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Also, further optimization of clone SM-20 through trunca-
tion and modifi cation to increase its bioavailability would 
prepare the molecule for translation into an in vivo model of 
breast cancer metastasis. These developmental steps could 
lead to a novel antimetastatic agent that has low to no toxic-
ity and is nonimmunogenic, making it an attractive agent to 
serve as an adjunct to traditional breast cancer therapy.
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